Postdoctoral Support

Internal Stanford funding opportunity in Maternal Child Health

DEADLINE:  Tuesday, September 4, 2018 - 5:00 PM

The Stanford Child Health Research Institute (CHRI) Postdoctoral Support funds innovative maternal and child health-focused clinical and translational research for postdoctoral fellows.

All projects must be significantly related to the health of expectant mothers and children. The applicant must be a pediatrician, obstetrician, a child health subspecialist, or scientist who has a focus on, or plans to focus on, child health research.

Note:  Clinical fellows (MD or equivalent) training in a clinical fellowship program should not apply through this mechanism.

Forms for Applicants


Awards will be announced in December 2018. Earliest award start date is January 1, 2019. The performance period is up to two years. 

Funding Amount

Postdoctoral Fellows  - $75,000 per year, up to two years

General Eligibility

•  All applicants must have, or plan on, having a focus on maternal child health research.

•  All applicants Primary Research Mentor must be a CHRI Member.

•  A Primary Research Mentor must be identified for postdoctoral fellows.

•  All applicants must have legal residence in the United States (Applicants with H or J visas are eligible).

•  The following are not eligible:

-  Clinician Educators (CEs)

-  Visiting scholars to Stanford

-  Senior Research Scientists, Research Associates/Assistants

-  Former recipients of CHRI/PRF/LPFCH-sponsored awards who have not complied with award/reporting requirements. Mentor or applicants who have overdraft(s) in previous awards that are not cleared prior to applying are not eligible.

Reviewer Form 

Funding Rates

YEAR # of Applications # of Awards
Funding Rate
Total Awarded
FY 18* 42 4 10% $412,500
FY 17 64 18 28% $947,000
FY 16 64 24 38% $1,129,000
FY 15 72 20 28% $1,000,000
FY 14 78 20 26% $932,000
FY 13 37 24 65% $1,156,000
FY 12 - - - -
FY 11 34 17 50% $594,988

*Only includes Fall 2017 cycle

Postdoctoral Support Panel Chairs

Professor of Pediatrics (Nephrology) at the Lucile Salter Packard Children's Hospital
Dunlevie Family Professor of Pulmonary Vascular Disease and Professor, by courts, of Bioengineering at the Lucile Salter Packard Children's Hospital
Shelagh Galligan Professor in the School of Medicine
(650) 725-7126


Dr. Sakamoto received her B.A. in Biology from Williams College and her M.D. from the University of Cincinnati. She was a pediatric resident and hematology/oncology fellow at Children’s Hospital Los Angeles. Dr. Sakamoto was a research fellow at UCLA and then was a faculty member at UCLA in the Department of Pediatrics, Division of Hematology/Oncology for over 20 years. She received her Ph.D. in Biology from the California Institute of Technology. Dr. Sakamoto was the Division Chief of Pediatric Hematology/Oncology at UCLA for six years and was the Vice-Chair of Research in the Department of Pediatrics; co-Associate Director of the Signal Transduction Program Area of the UCLA Jonsson Comprehensive Cancer Center, and co-Chair of the UCLA Clinical and Translational Science Institute, Committee for Maternal, Child, and Adolescent Health. From 2011-2014, she was the Division Chief of Pediatric Hematology/Oncology/Stem Cell Transplant/Cancer Biology at Lucile Packard Children’s Hospital at Stanford. Dr. Sakamoto was the Fellowship Program Director and is the P.I. of an NIH T32 training grant at Stanford. Currently, she is a member of the Child Health Research Institute Executive Committee at Stanford University and the Academic Promotion Committee for Stanford School of Medicine. Dr. Sakamoto’s research has focused on signaling pathways and gene regulation in normal and aberrant hematopoiesis, including leukemia and bone marrow failure syndromes. She is specifically interested in targeted therapies for leukemia and other types of pediatric cancers. Dr. Sakamoto has been funded by the National Institutes of Health for over 20 years. She currently holds the Shelagh Galligan Endowed Professorship and has received awards from the American Cancer Society, Leukemia & Lymphoma Society, Bear Necessities, and CDMRP(DOD). She has been a standing and ad hoc member of National Institutes of Health grant review committees for the past 15 years. She is Chair of the Bear Necessities Scientific Review Committee. She is currently developing novel therapies to target CREB for the treatment of acute leukemia. Promising small molecule compounds that are effective in the lab and nontoxic will be tested and optimized to take to the clinic for patients with relapsed leukemia. This will provide novel approaches to treat leukemia in children.
NICU Nurses Professor and Professor (Research), by courtesy, of Health Research and Policy (Epidemiology) and of Obstetrics and Gynecology (Maternal Fetal Medicine)
Professor of Pediatrics (Hematology/Oncology) and of Genetics
Associate Professor of Urology at the Stanford University Medical Center

Please contact CHRI Administration or 650-724-6891 with any questions.